The evidence begins to pile up here (as the lawsuits continue to roll in). To wit: unless an older woman has full-on osteoporosis, it may no longer make sense for her to be on Fosamax® for any extended period of time (three or more years), without a drug holiday.
Per Bloomberg reporting, tonight:
. . . .Merck’s Fosamax was the first bisphosphonate marketed to treat and prevent osteoporosis in older women. The drug reached sales of $3.19 billion in 2005 before facing competition from cheaper generic copies. The drug had sales of $926 million last year, according to data compiled by Bloomberg. Merck is based in Whitehouse Station, New Jersey. . . .
Three previous studies were unable to prove a link between bisphosphonates and the atypical fractures. Those studies were smaller and focused mostly on women who took the drug for fewer than five years, the researchers said.
Today’s research, funded by the Ontario Ministry of Health, examined records of 205,466 women over the age of 68 who were treated with bisphosphonates between 2002 and 2008. Scientists identified 716 women who had the atypical fractures. . . .
We’ll keep you posted.